Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data. Retevmo (selpercatinib) significantly improved event-free ...
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results